Novartis eyes double blockbuster potential for Genmab-developed drug
![Photo: ARND WIEGMANN/REUTERS / X90184](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14431411.ece/ALTERNATES/schema-16_9/doc7mvdlfv2fdzdasv5eij.jpg)
Sclerosis treatment Kesimpta (ofatumumab) will surpass annual sales of USD 2bn over the coming years, said Novartis, the company marketing the drug, on Thursday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.